We are live on ! Find out more
SCM

Sarissa Capital Management Portfolio holdings

AUM $158M
1-Year Est. Return 103.7%
This Fund
S&P 500
This Quarter Est. Return
+15.9%
1 Year Est. Return
+103.7%
3 Year Est. Return
+58.62%
5 Year Est. Return
+92.85%
10 Year Est. Return
+667.68%
AUM
$840M
AUM Growth
-$44.6M
Cap. Flow
-$166M
Cap. Flow %
-19.73%
Top 10 Hldgs %
99.97%
Holding
11
New
–
Increased
–
Reduced
4
Closed
–

Top Buys

No buys this quarter

Top Sells

Rank Stock Value
1
ALKS icon
Alkermes
ALKS
+$121M
2
AMRN
Amarin Corp
AMRN
+$23M
3
GILD icon
Gilead Sciences
GILD
+$16.2M
4
BCRX icon
BioCryst Pharmaceuticals
BCRX
+$5.12M

Sector Composition

Rank Sector Weight
1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ALKS icon
1
Alkermes
ALKS
$8.22B
$234M 27.88%
8,964,640
-5,075,360
-36% -$121M
IRWD icon
2
Ironwood Pharmaceuticals
IRWD
$696M
$203M 24.17%
16,390,000
– –
BIIB icon
3
Biogen
BIIB
$30B
$178M 21.19%
643,000
– –
GILD icon
4
Gilead Sciences
GILD
$162B
$91.8M 10.92%
1,068,750
-204,350
-16% -$16.2M
INVA icon
5
Innoviva
INVA
$1.55B
$87.6M 10.43%
6,614,000
– –
MRSN
6
DELISTED
Mersana Therapeutics
MRSN
$23.4M 2.79%
159,880
– –
BCRX icon
7
BioCryst Pharmaceuticals
BCRX
$2.28B
$11.3M 1.34%
980,288
-410,502
-30% -$5.12M
AMRN
8
Amarin Corp
AMRN
$299M
$5.82M 0.69%
240,350
-959,550
-80% -$23M
VOR icon
9
Vor Biopharma
VOR
$1.15B
$4.11M 0.49%
30,900
– –
PEAR
10
DELISTED
Pear Therapeutics, Inc. Class A Common Stock
PEAR
$590K 0.07%
500,356
– –
RGLS
11
DELISTED
Regulus Therapeutics
RGLS
$254K 0.03%
185,183
– –

Similar funds

4A
4D Advisors Redondo Beach, California $158M AUM 92.73% 1-Year Est. Return
DAM
Deepwater Asset Management Minneapolis, Minnesota $158M AUM 23.9% 1-Year Est. Return
PCP
Pantera Capital Partners San Francisco, California $158M AUM 600.89% 1-Year Est. Return
CF
CDC Financial Chicago, Illinois $157M AUM
HEM
Henson-Edgewater Management Avon, Ohio $157M AUM
SF
Seros Financial Tempe, Arizona $157M AUM 16.95% 1-Year Est. Return
AC
AlpenGlobal Capital Tahoe City, California $157M AUM
EP
Elkhorn Partners Omaha, Nebraska $157M AUM 11.91% 1-Year Est. Return

Sarissa Capital Management's Q4 2022 Portfolio in Review

As of Q4 2022, Sarissa Capital Management held 11 positions worth $840M, down 5% from $885M the previous quarter. Its ten largest holdings account for 100% of the portfolio.

Sarissa Capital Management withdrew a net $166M in Q4 2022, reducing 4 holdings. Its largest reduction was Alkermes, cutting an estimated $121M.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, unchanged from a quarter earlier.

  • Sarissa Capital Management's biggest Q4 2022 reduction was Alkermes, cutting an estimated $121M.
  • Sarissa Capital Management's ten largest holdings make up 100% of its $840M portfolio in Q4 2022.
  • Sarissa Capital Management opened 0 new positions and closed 0 in Q4 2022.
  • Sarissa Capital Management's portfolio value fell 5% quarter-over-quarter to $840M.

Based on Sarissa Capital Management's 13F filing for Q4 2022, filed 14 Feb 2023.